Trump's FDA nominee Heidi Overton previously opposed gender-affirming care for minors

On August 20, 2026, President Trump nominated physician Heidi Overton to become the new commissioner of the U.S. Food and Drug Administration (FDA), the federal regulator responsible for approving medicines, medical devices and hormone treatments, among other things. Overton is no stranger to the U.S. healthcare debate: while working as a policy adviser at the conservative America First Policy Institute, she previously wrote critical analyses of gender-affirming care for minors and raised questions about the safety of abortion pills prescribed via telehealth. Her nomination still needs to be confirmed by the Senate; Senator Patty Murray has already announced that she will vote against it.

A critic at the helm of the drug regulator

The FDA plays a role in determining which medical treatments, including puberty blockers and gender-affirming hormones, remain approved for the U.S. market and under what conditions. That makes the person leading the agency relevant to the broader debate over gender-affirming care for children and adolescents. Overton is among a group of physicians who have publicly questioned the scientific basis for gender-affirming treatment pathways for minors in recent years — a position that aligns with the Trump administration's stance, which previously sought to restrict federal funding for this type of care for children.

Resistance in the Senate

Not everyone is convinced. Senator Patty Murray, a Democrat from Washington state and a longtime member of the Senate Health Committee, immediately announced that she would vote against confirmation. Critics point out that Overton also previously questioned the safety of medication abortion via telehealth, which is expected to make the confirmation hearing one of the most contentious of the fall. Supporters of the nomination argue that Overton would bring the FDA closer to stricter, evidence-based scrutiny of medical interventions for minors, in line with the conclusions of earlier critical reviews such as the UK's Cass Review.

Part of a broader approach

Overton's nomination does not stand alone. In recent months, the Trump administration has already implemented a series of measures restricting access to and funding for gender-affirming care for minors, ranging from investigations into fraudulent insurance claims to lawsuits against hospitals that provided such care. An FDA commissioner who has previously written critically about these treatments could further entrench that policy through drug regulation — for example, in future assessments of medicines used specifically for puberty suppression or hormone therapy in young people.